<SEC-DOCUMENT>0001645113-23-000027.txt : 20230302
<SEC-HEADER>0001645113-23-000027.hdr.sgml : 20230302
<ACCEPTANCE-DATETIME>20230302165526
ACCESSION NUMBER:		0001645113-23-000027
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230228
FILED AS OF DATE:		20230302
DATE AS OF CHANGE:		20230302

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Cordova Ashley
		CENTRAL INDEX KEY:			0001822014

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37565
		FILM NUMBER:		23699984

	MAIL ADDRESS:	
		STREET 1:		20 VALLEY STREAM PARKWAY,
		STREET 2:		SUITE 300
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NovoCure Ltd
		CENTRAL INDEX KEY:			0001645113
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		NO. 4 THE FORUM
		STREET 2:		GRENVILLE STREET
		CITY:			ST. HELIER
		STATE:			Y9
		ZIP:			JE2 4UF
		BUSINESS PHONE:		44 (0)15 3475 6700

	MAIL ADDRESS:	
		STREET 1:		NO. 4 THE FORUM
		STREET 2:		GRENVILLE STREET
		CITY:			ST. HELIER
		STATE:			Y9
		ZIP:			JE2 4UF

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Novocure Ltd
		DATE OF NAME CHANGE:	20150615
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>wf-form4_167779410749716.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-02-28</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001645113</issuerCik>
        <issuerName>NovoCure Ltd</issuerName>
        <issuerTradingSymbol>NVCR</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001822014</rptOwnerCik>
            <rptOwnerName>Cordova Ashley</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O NOVOCURE INC.,</rptOwnerStreet1>
            <rptOwnerStreet2>1550 LIBERTY RIDGE DRIVE, SUITE 115</rptOwnerStreet2>
            <rptOwnerCity>WAYNE</rptOwnerCity>
            <rptOwnerState>PA</rptOwnerState>
            <rptOwnerZipCode>19087</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Financial Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
            </securityTitle>
            <transactionDate>
                <value>2023-02-28</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>23818</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>98260</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
            </securityTitle>
            <transactionDate>
                <value>2023-03-01</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>2198</value>
                    <footnoteId id="F2"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>76.3624</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>96062</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Options to Buy Ordinary Shares</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>76.97</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-02-28</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>39614</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>76.97</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2024-02-28</value>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-02-27</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>39614.0</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>39614</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.</footnote>
        <footnote id="F2">Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a &quot;sell to cover&quot; transaction and does not represent a discretionary trade by the reporting person.</footnote>
        <footnote id="F3">Options to buy 39,614 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>By: /s/ Steven Robbins, Attorney in Fact for Ashley Cordova</signatureName>
        <signatureDate>2023-03-02</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
